



Discovery Fueled by Ultra-Sensitivity

## Quanterix to Present at Cowen's 44th Annual Health Care Conference

Feb 23, 2024

BILLERICA, Mass.--(BUSINESS WIRE)--Feb. 23, 2024-- [Quanterix Corporation](#) (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will present at Cowen's 44th Annual Health Care Conference. Quanterix's session will take place on Monday, March 4, 2024, at 12:50 p.m. EST and will be made available to attendees and, via webcast, the general public. In addition to the session, Quanterix will also host one-on-one meetings with institutional investors during the conference.

Cowen's 44th Annual Health Care Conference will take place March 4 - 6, 2024, in Boston, MA. The conference incorporates presentations, fireside chats and panel discussions hosted by members of the Cowen research team that focus on various aspects of the health care industry.

### Webcast Information

To access the live audio webcast of Quanterix's presentation at the conference, please visit: <https://wsw.com/webcast/cowen154/qtrx/2067466>. Quanterix's session will take place on Monday, March 4, 2024, at 12:50 p.m. EST.

Replays of the presentation will be available for a limited period following the conference. The presentation will also be made available through the Investor Relations section of Quanterix's website.

To learn more about Quanterix, visit [www.quanterix.com/about](http://www.quanterix.com/about). To learn more about Quanterix's Simoa® technology, visit: [www.quanterix.com/simoa-technology/](http://www.quanterix.com/simoa-technology/).

### About Quanterix

From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa<sup>®</sup> technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,700 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at <https://www.quanterix.com> or follow us on [Twitter](#) and [LinkedIn](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240223277311/en/): <https://www.businesswire.com/news/home/20240223277311/en/>

### Media Contact:

PAN Communications  
Maya Nimnicht  
510-334-6273  
[quanterix@pancomm.com](mailto:quanterix@pancomm.com)

### Investor Relations Contact:

Amy Achorn  
(978) 488-1854  
[ir@quanterix.com](mailto:ir@quanterix.com)

Source: Quanterix Corporation